Welcome to our dedicated page for Xtant Medical news (Ticker: XTNT), a resource for investors and traders seeking the latest updates and insights on Xtant Medical stock.
Xtant Medical Holdings, Inc. (XTNT) is a leader in regenerative medicine, specializing in orthobiologics and spinal implant systems for complex surgical procedures. This page aggregates official company news, including product developments, financial updates, and strategic initiatives within the orthopedic and neurological sectors.
Investors and healthcare professionals will find verified press releases covering regulatory milestones, partnership announcements, and advancements in bone healing technologies. Our repository ensures access to timely updates on Xtant Medical's surgical solutions, including spinal fusion devices and biologics designed to improve patient outcomes.
Bookmark this page for direct access to earnings reports, acquisition news, and clinical trial progress. All content is sourced from official channels to maintain accuracy and compliance with financial disclosure standards.
Xtant Medical Holdings (NYSE American: XTNT), a global medical technology company specializing in surgical solutions for spinal disorders, has announced its upcoming second quarter 2024 financial results release and earnings conference call. The company will disclose its financial results for the quarter ended June 30, 2024, after market close on Thursday, August 8, 2024.
A conference call to discuss the results is scheduled for Friday, August 9, 2024, at 9:00 AM ET. The call will be hosted by Sean Browne, President and CEO, and Scott Neils, CFO. Investors can join via phone or webcast, with replay available on the company's website post-call.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) reported strong financial results for Q2 2024, with revenue increasing 48% to $29.9 million. The company's gross margin improved by 50 basis points to 62.1%. Despite a net loss of $3.9 million, Xtant achieved positive Adjusted EBITDA of $0.5 million.
Key highlights include the launch of two new amniotic membrane allograft products, signing 15 new distributors, and securing 20 IDN contracts. The company also entered a $5.0 million private placement to strengthen its balance sheet.
Xtant reaffirmed its 2024 revenue guidance of $116-$120 million, projecting 27-31% annual growth. The company expects continued momentum with new product launches, increased distributor penetration, and improved margins in the second half of 2024.
Xtant Medical Holdings (NYSE American: XTNT), a global medical technology company specializing in spinal disorder treatments, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase. The event will take place from August 13-15, 2024 at the InterContinental Boston.
Sean Browne, President and CEO, and Scott Neils, CFO, will represent Xtant Medical at the conference. Browne is scheduled to present on Wednesday, August 14th at 11:00 a.m. Eastern. Investors and interested parties can access a video webcast of the presentation through the provided link.
This conference participation offers Xtant Medical an opportunity to showcase its surgical solutions and connect with potential investors and industry professionals.
Xtant Medical, a global medical technology company specializing in spinal disorder treatments, will participate in the 21st Annual Craig-Hallum Institutional Investor Conference on May 29, 2024, in Minneapolis. CEO Sean Browne and CFO Scott Neils will represent the company. The event, featuring over 130 public companies, includes one-on-one and small group meetings. Interested parties can schedule a meeting by contacting Brett Maas or their Craig Hallum representative. Additionally, the company's investor presentation is available on Xtant Medical's investor relations website.
Xtant Medical (NYSE American:XTNT) reported a 55% revenue increase for Q1 2024, reaching $27.9 million compared to $17.9 million in Q1 2023. The growth was driven by acquisitions and increased sales of Coflex and CoFix products.
Gross margin improved to 62.1%, up from 58.7% in the prior year. However, the company recorded a net loss of $4.3 million, higher than the $2.1 million loss in Q1 2023. Adjusted EBITDA turned positive at $0.1 million from a loss of $0.3 million in the previous year.
Xtant launched two new amniotic membrane allografts and amended credit agreements for more working capital. The company raised its 2024 revenue guidance to $116 million - $120 million, indicating a 27%-31% growth compared to 2023.
Apyx Medical announced the retirement of Andrew Makrides as Chairman of the Board, who served the company since 1982, and the appointment of Stavros Vizirgianakis as the new Chairman. Makrides contributed to the company's growth over the years, while Vizirgianakis brings extensive medical device industry experience to the role.
Xtant Medical Holdings, Inc. (NYSE American:XTNT) will release its first quarter 2024 financial results on May 15, 2024. The global medical technology company specializing in spinal disorder surgical solutions will have a conference call hosted by President Sean Browne and CFO Scott Neils at 4:30 PM ET on the same day. Details can be accessed through the provided conference dial-in or webcast link.
Xtant Medical Holdings, Inc. announced the full commercial launch of two amniotic membrane allografts, SimpliGraft™ and SimpliMax™, for chronic and acute wounds. The products are dehydrated, terminally irradiated, single and dual-layer amniotic membrane sheets intended to provide protective coverage from the surrounding environment when applied topically. Manufactured at Xtant’s biologics processing center in Belgrade, Montana, the company aims to position itself as a leader and innovator in advanced biologic therapies.
FAQ
What is the current stock price of Xtant Medical (XTNT)?
What is the market cap of Xtant Medical (XTNT)?
